Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

A Novel Interaction Between the TLR7 and a Colchicine Derivative Revealed Through a Computational and Experimental Study.

Gentile F, Deriu MA, Barakat K, Danani A, Tuszynski J.

Pharmaceuticals (Basel). 2018 Feb 16;11(1). pii: E22. doi: 10.3390/ph11010022.

2.

Imidazoquinoxaline anticancer derivatives and imiquimod interact with tubulin: Characterization of molecular microtubule inhibiting mechanisms in correlation with cytotoxicity.

Courbet A, Bec N, Constant C, Larroque C, Pugniere M, El Messaoudi S, Zghaib Z, Khier S, Deleuze-Masquefa C, Gattacceca F.

PLoS One. 2017 Aug 10;12(8):e0182022. doi: 10.1371/journal.pone.0182022. eCollection 2017.

3.

Structure Based Modeling of Small Molecules Binding to the TLR7 by Atomistic Level Simulations.

Gentile F, Deriu MA, Licandro G, Prunotto A, Danani A, Tuszynski JA.

Molecules. 2015 May 8;20(5):8316-40. doi: 10.3390/molecules20058316.

4.

The Toll-like receptor 7/8-ligand resiquimod (R-848) primes human neutrophils for leukotriene B4, prostaglandin E2 and platelet-activating factor biosynthesis.

Hattermann K, Picard S, Borgeat M, Leclerc P, Pouliot M, Borgeat P.

FASEB J. 2007 May;21(7):1575-85. Epub 2007 Jan 30.

PMID:
17264163
5.

Design of anti-BVDV drug based on common chemical features, their interaction, and scaffolds of TLR8 agonists.

Chai HH, Lim D, Suk JE, Choi BH, Cho YM.

Int J Biol Macromol. 2016 Nov;92:1095-1112. doi: 10.1016/j.ijbiomac.2016.08.022. Epub 2016 Aug 9.

6.

Discovery of novel tubulin inhibitors via structure-based hierarchical virtual screening.

Cao R, Liu M, Yin M, Liu Q, Wang Y, Huang N.

J Chem Inf Model. 2012 Oct 22;52(10):2730-40. doi: 10.1021/ci300302c. Epub 2012 Oct 2.

PMID:
22992059
7.

Computational design and biological testing of highly cytotoxic colchicine ring A modifications.

Torin Huzil J, Winter P, Johnson L, Weis AL, Bakos T, Banerjee A, Luduena RF, Damaraju S, Tuszynski JA.

Chem Biol Drug Des. 2010 Jun;75(6):541-50. doi: 10.1111/j.1747-0285.2010.00970.x. Epub 2010 Apr 8.

PMID:
20408852
8.

TLR7 and TLR8 as targets in cancer therapy.

Schön MP, Schön M.

Oncogene. 2008 Jan 7;27(2):190-9. doi: 10.1038/sj.onc.1210913. Review.

PMID:
18176600
9.

Modulating responsiveness of human TLR7 and 8 to small molecule ligands with T-rich phosphorothiate oligodeoxynucleotides.

Jurk M, Kritzler A, Schulte B, Tluk S, Schetter C, Krieg AM, Vollmer J.

Eur J Immunol. 2006 Jul;36(7):1815-26.

10.
11.

The antiviral activity of Toll-like receptor 7 and 7/8 agonists.

Miller RL, Meng TC, Tomai MA.

Drug News Perspect. 2008 Mar;21(2):69-87. Review.

PMID:
18389099
12.

The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily.

Heil F, Ahmad-Nejad P, Hemmi H, Hochrein H, Ampenberger F, Gellert T, Dietrich H, Lipford G, Takeda K, Akira S, Wagner H, Bauer S.

Eur J Immunol. 2003 Nov;33(11):2987-97.

13.

Stoichiometric and substoichiometric inhibition of tubulin self-assembly by colchicine analogues.

Perez-Ramirez B, Andreu JM, Gorbunoff MJ, Timasheff SN.

Biochemistry. 1996 Mar 12;35(10):3277-85.

PMID:
8605164
14.

Regioisomerism-dependent TLR7 agonism and antagonism in an imidazoquinoline.

Shukla NM, Kimbrell MR, Malladi SS, David SA.

Bioorg Med Chem Lett. 2009 Apr 15;19(8):2211-4. doi: 10.1016/j.bmcl.2009.02.100. Epub 2009 Feb 28.

PMID:
19285861
15.

A novel TLR7 agonist reverses NK cell anergy and cures RMA-S lymphoma-bearing mice.

Wiedemann GM, Jacobi SJ, Chaloupka M, Krächan A, Hamm S, Strobl S, Baumgartner R, Rothenfusser S, Duewell P, Endres S, Kobold S.

Oncoimmunology. 2016 May 31;5(7):e1189051. doi: 10.1080/2162402X.2016.1189051. eCollection 2016 Jul.

16.

The TLR7/8 ligand resiquimod targets monocyte-derived dendritic cell differentiation via TLR8 and augments functional dendritic cell generation.

Hackstein H, Knoche A, Nockher A, Poeling J, Kubin T, Jurk M, Vollmer J, Bein G.

Cell Immunol. 2011;271(2):401-12. doi: 10.1016/j.cellimm.2011.08.008. Epub 2011 Aug 22.

PMID:
21889130
17.

[Expression of Toll-like receptor 7 in gastric cancer cell lines and effects of TLR7 agonist on proliferation and apoptosis of SGC-7901 cells in vitro].

Jiang J, Dong L, Qin B, Guo X, Li H, Shi H, Liu Y.

Nan Fang Yi Ke Da Xue Xue Bao. 2014 Nov;34(11):1606-10. Chinese.

PMID:
25413058
18.

Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod.

Gibson SJ, Lindh JM, Riter TR, Gleason RM, Rogers LM, Fuller AE, Oesterich JL, Gorden KB, Qiu X, McKane SW, Noelle RJ, Miller RL, Kedl RM, Fitzgerald-Bocarsly P, Tomai MA, Vasilakos JP.

Cell Immunol. 2002 Jul-Aug;218(1-2):74-86.

PMID:
12470615
19.

The therapeutic potential of Toll-like receptor 7 stimulation in asthma.

Drake MG, Kaufman EH, Fryer AD, Jacoby DB.

Inflamm Allergy Drug Targets. 2012 Dec;11(6):484-91. Review.

20.

Association between Toll-like receptor 7 Gln11Leu single-nucleotide polymorphism and basal cell carcinoma.

Russo I, Cona C, Saponeri A, Bassetto F, Baldo V, Alaibac M.

Biomed Rep. 2016 Apr;4(4):459-462. Epub 2016 Feb 15.

Supplemental Content

Support Center